Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: Stable radiographic disease with decreased AFP |
| |
Authors: | Marsh Anne M Lo Louise Cohen Ronald A Feusner James H |
| |
Affiliation: | Department of Hematology/Oncology, Children's Hospital and Research Center Oakland, Oakland, California. |
| |
Abstract: | We report the use of sorafenib and bevacizumab in combination for a patient with recurrent metastatic hepatoblastoma (HB). This combination demonstrated activity against our patient's refractory HB that had been extensively treated with multiple prior chemotherapeutic regimens. The patient had stabilization of radiographic disease coupled with an 83% decrease in his alpha‐fetoprotein level. Given the response in this setting and the paucity of other available options, consideration could be given to using this combination as therapy in patients with recurrent HB who have failed more traditional agents. Pediatr Blood Cancer 2012; 59: 939–940. © 2012 Wiley Periodicals, Inc. |
| |
Keywords: | hepatoblastoma new agents pediatric oncology |
本文献已被 PubMed 等数据库收录! |